The effect of a polyurethane coating incorporating both a thrombin inhibitor and nitric oxide on hemocompatibility in extracorporeal circulation

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7271-7285

  Major, Terry C ^a   Brisbois, Elizabeth J ^b   Jones, Anna M ^a   Zanetti, Margaux E ^a   Annich, Gail M ^c   Bartlett, Robert H ^a   Handa, Hitesh ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Argatroban; Direct thrombin inhibition; Hexane methylene diisocyanate (HMDI); Nitric oxide releasing polymer; Polyethylene glycol (PEG); Thrombogenicity

Indexed keywords

ENZYMES; GRAFTS; HEXANE; NITRIC OXIDE; PLATELETS; POLYETHYLENE GLYCOLS; POLYMER FILMS; POLYURETHANES;

ARGATROBAN; DIISOCYANATES; POLYETHYLENE GLYCOL (PEG); THROMBIN INHIBITION; THROMBOGENICITY;

PLASTIC COATINGS;

ARGATROBAN; CARBENE; COLLAGEN; FIBRINOGEN; HEXANE; MACROGOL; NITRIC OXIDE; PADGEM PROTEIN; POLYMER; POLYURETHAN; PROTON; 1,6-HEXAMETHYLENE DIISOCYANATE; ANTITHROMBIN; BIOMATERIAL; ISOCYANIC ACID DERIVATIVE; MACROGOL DERIVATIVE; PIPECOLIC ACID DERIVATIVE; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD; BLOOD CLOTTING; CONTROLLED STUDY; EX VIVO STUDY; EXTRACORPOREAL CIRCULATION; FIBRINOGEN BLOOD LEVEL; FILM; FLOW CYTOMETRY; FLUORESCENCE; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; STIMULATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOGENICITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING PARAMETERS; CHEMISTRY; CYTOLOGY; DEVICES; DRUG EFFECTS; RABBIT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD PLATELETS; COATED MATERIALS, BIOCOMPATIBLE; EXTRACORPOREAL CIRCULATION; ISOCYANATES; NITRIC OXIDE; PIPECOLIC ACIDS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; POLYETHYLENE GLYCOLS; POLYMERS; POLYURETHANES; RABBITS; THROMBIN; THROMBOSIS;

EID: 84902536241     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.036     Document Type: Article

References (50)

1. Ranucci M., Pazzaglia A., Isgro G., Cazzaniga A., Ditta A., Boncilli A., et al. Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept. Int J Artif Organs 2002, 25:875-881.
2. Conn G., Kidane A.G., Punshon G., Kannan R.Y., Hamilton G., Seifalian A.M. Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?. Expert Rev Med Devices 2006, 3:245-261.
3. Major T.C., Brant D.O., Reynolds M.M., Bartlett R.H., Meyerhoff M.E., Handa H., et al. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials 2010, 31:2736-2745.
4. Skrzypchak A.M., Lafayette N.G., Bartlett R.H., Zhou Z., Frost M.C., Meyerhoff M.E., et al. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an invivo model of extracorporeal circulation. Perfusion 2007, 22:193-200.
5. Major T.C., Handa H., Brisbois E.J., Reynolds M.M., Annich G.M., Meyerhoff M.E., et al. The mediation of platelet quiescence by NO-releasing polymers via cGMP-induced serine 239 phosphorylation of vasodilator-stimulated phosphoprotein. Biomaterials 2013, 34:8086-8096.
6. Zhang H., Annich G.M., Miskulin J., Osterholzer K., Merz S.I., Bartlett R.H., et al. Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and invivo evaluation. Biomaterials 2002, 23:1485-1494.
7. Reynolds M.M., Frost M.C., Meyerhoff M.E. Nitric oxide-releasing hydrophobic polymers: preparation, characterization, and potential biomedical applications. Free Radic Biol Med 2004, 37:926-936.
8. Frost M.C., Reynolds M.M., Meyerhoff M.E. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials 2005, 26:1685-1693.
9. Annich G.M., Meinhardt J.P., Mowery K.A., Ashton B.A., Merz S.I., Hirschl R.B., et al. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med 2000, 28:915-920.
10. Frank R.D., Muller U., Lanzmich R., Groeger C., Floege J. Anticoagulant-free genius haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant 2006, 21:1013-1018.
11. Bush L.R. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991, 9:247-263.
12. Sabatine M.S., Tu T.M., Jang I.K. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. JThromb Thrombolysis 2000, 10:189-196.
13. Murphy K.D., Galla D.H., Vaughn C.J., McCrohan G., Garrisi W.J. Heparin-induced thrombocytopenia and thrombosis syndrome. Radiographics 1998, 18:111-120.
14. Batchelor M.M., Reoma S.L., Fleser P.S., Nuthakki V.K., Callahan R.E., Shanley C.J., et al. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. JMed Chem 2003, 46:5153-5161.
15. Massaguer A., Engel P., Perez-del-Pulgar S., Bosch J., Pizcueta P. Production and characterization of monoclonal antibodies against conserved epitopes of P-selectin (CD62P). Tissue Antigens 2000, 56:117-128.
16. Gosselin R.C., King J.H., Janatpur K.A., Dager W.H., Larkin E.C., Owings J.T. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004, 128:1142-1145.
17. Handa H., Brisbois E.J., Major T.C., Refahiyat L., Amoako K.A., Annich G.M., et al. Invitro and invivo study of sustained nitric oxide release coating using diazeniumdiolate-doped poly(vinyl chloride) matrix with poly(lactide-co-glycolide) additive. JMater Chem B Mater Biol Med 2013, 1:3578-3587.
18. Andrews R.K., Berndt M.C. Platelet physiology and thrombosis. Thromb Res 2004, 114:447-453.
19. El-Sabbagh A.M., Toomasian C.J., Toomasian J.M., Ulysse G., Major T., Bartlett R.H. Effect of air exposure and suction on blood cell activation and hemolysis in an invitro cardiotomy suction model. ASAIO J 2013, 59:474-479.
20. Ilmakunnas M., Pesonen E.J., Ahonen J., Ramo J., Siitonen S., Repo H. Activation of neutrophils and monocytes by a leukocyte-depleting filter used throughout cardiopulmonary bypass. JThorac Cardiovasc Surg 2005, 129:851-859.
21. Yeh R.W., Jang I.K. Argatroban: update. Am Heart J 2006, 151:1131-1138.
22. Clark T.W., Jacobs D., Charles H.W., Kovacs S., Aquino T., Erinjeri J., et al. Comparison of heparin-coated and conventional split-tip hemodialysis catheters. Cardiovasc Interv Radiol 2009, 32:703-706.
23. Wu B., Gerlitz B., Grinnell B.W., Meyerhoff M.E. Polymeric coatings that mimic the endothelium: combining nitric oxide release with surface-bound active thrombomodulin and heparin. Biomaterials 2007, 28:4047-4055.
24. Du Y.J., Brash J.L., McClung G., Berry L.R., Klement P., Chan A.K. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex. JBiomed Mater Res A 2007, 80:216-225.
25. Zimmermann A.K., Weber N., Aebert H., Ziemer G., Wendel H.P. Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. JBiomed Mater Res B Appl Biomater 2007, 80:433-439.
26. Beiderlinden M., Treschan T., Gorlinger K., Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007, 31:461-465.
27. Ying H., Zhang Y., Cheng J. Dynamic urea bond for the design of reversible and self-healing polymers. Nat Commun 2014, 5:3218.
28. Balakrishnan B., Kumar D.S., Yoshida Y., Jayakrishnan A. Chemical modification of poly(vinyl chloride) resin using poly(ethylene glycol) to improve blood compatibility. Biomaterials 2005, 26:3495-3502.
29. Richey T., Iwata H., Oowaki H., Uchida E., Matsuda S., Ikada Y. Surface modification of polyethylene balloon catheters for local drug delivery. Biomaterials 2000, 21:1057-1065.
30. Kruse K.R., Crowley J.J., Tanguay J.F., Santos R.M., Millare D.S., Phillips H.R., et al. Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model. Catheter Cardiovasc Interv 1999, 46:503-507.
31. Noguchi H., Iwata H., Ikada Y. Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond. JBiomed Mater Res 1998, 39:621-629.
32. Banner D.W., Hadvary P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. JBiol Chem 1991, 266:20085-20093.
33. Handa H., Major T.C., Brisbois E.J., Amoako K.A., Meyerhoff M.E., Bartlett R.H. Hemocompatibility comparison of biomedical grade polymers using rabbit thrombogenicity model for preparing nonthrombogenic nitric oxide releasing surfaces. JMater Chem B Mater Biol Med 2014, 2:1059-1067.
34. Gao X., Kucerka N., Nieh M.P., Katsaras J., Zhu S., Brash J.L., et al. Chain conformation of a new class of PEG-based thermoresponsive polymer brushes grafted on silicon as determined by neutron reflectometry. Langmuir 2009, 25:10271-10278.
35. Zhang Z., Zhang M., Chen S., Horbett T.A., Ratner B.D., Jiang S. Blood compatibility of surfaces with superlow protein adsorption. Biomaterials 2008, 29:4285-4291.
36. Hoffmann J., Groll J., Heuts J., Rong H., Klee D., Ziemer G., et al. Blood cell and plasma protein repellent properties of star-PEG-modified surfaces. JBiomater Sci Polym Ed 2006, 17:985-996.
37. Feng W., Zhu S., Ishihara K., Brash J.L. Protein resistant surfaces: comparison of acrylate graft polymers bearing oligo-ethylene oxide and phosphorylcholine side chains. Biointerphases 2006, 1:50.
38. Wu Y., Simonovsky F.I., Ratner B.D., Horbett T.A. The role of adsorbed fibrinogen in platelet adhesion to polyurethane surfaces: a comparison of surface hydrophobicity, protein adsorption, monoclonal antibody binding, and platelet adhesion. JBiomed Mater Res A 2005, 74:722-738.
39. Reynolds M.M., Hrabie J.A., Oh B.K., Politis J.K., Citro M.L., Keefer L.K., et al. Nitric oxide releasing polyurethanes with covalently linked diazeniumdiolated secondary amines. Biomacromolecules 2006, 7:987-994.
40. Zhou Z., Meyerhoff M.E. Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. Biomaterials 2005, 26:6506-6517.
41. Fleser P.S., Nuthakki V.K., Malinzak L.E., Callahan R.E., Seymour M.L., Reynolds M.M., et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. JVasc Surg 2004, 40:803-811.
42. Musashi K., Kiryu J., Miyamoto K., Miyahara S., Katsuta H., Tamura H., et al. Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation. Invest Ophthalmol Vis Sci 2005, 46:2561-2566.
43. Kanemitsu S., Nishikawa M., Onoda K., Shimono T., Shimpo H., Yazaki A., et al. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during invitro extracorporeal circulation. JThorac Cardiovasc Surg 2003, 126:428-435.
44. Miyahara S., Kiryu J., Tsujikawa A., Katsuta H., Nishijima K., Miyamoto K., et al. Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. Stroke 2003, 34:2043-2049.
45. Amin H.M., Ahmad S., Walenga J.M., Hoppensteadt D.A., Leitz H., Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000, 6:71-76.
46. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97:251-256.
47. Kaiser B., Koza M., Walenga J.M., Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res 1996, 82:257-263.
48. Rao N.V., Argyle B., Xu X., Reynolds P.R., Walenga J.M., Prechel M., et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 2010, 299:C97-C110.
49. Alberti S., Angeloni G., Tamburrelli C., Pampuch A., Izzi B., Messano L., et al. Platelet-leukocyte mixed conjugates in patients with atrial fibrillation. Platelets 2009, 20:235-241.
50. Li N., He S., Blomback M., Hjemdahl P. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol 2007, 27:407-413.